Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Expression and Prognostic Significance of Stem Cell Marker Cd133 in Survival Rate of Patients With Colon Cancer Publisher



Ehteram H1 ; Aslanbeigi F2, 3 ; Ghoochani Khorasani E4 ; Tolouee M6 ; Haddad Kashani H5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
  2. 2. School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
  3. 3. Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
  4. 4. Isabn-e-Maryam Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
  6. 6. Kashan University of Medical Sciences, Kashan, Iran

Source: Oncology and Therapy Published:2022


Abstract

Introduction: Today, colon cancer is one of the most common types of gastrointestinal cancer worldwide. CD133 as a known cancer stem cell marker has been found effective in cell proliferation and differentiation in various cancers, including colon cancer. We aimed to investigate the relationship between CD133 expression in colon cancer with prognostic factors and survival rate of patients with colon cancer by immunohistochemistry. Methods: Formalin-fixed paraffin-embedded (FFPE) tissue was taken from patients with colon cancer. Histopathology examination was done using hematoxylin and eosin staining. Immunohistochemistry was performed to determine CD133 expression. Association between CD133 expression and clinicopathological profile was then assessed. Results: There was a statistically significant association between CD133 protein expression and sex , cancer stage, and lymphatic invasion (p = 0.044, p = 0.131, and p = 0.002, respectively). However, no significant correlation was identified between CD133 expression and other factors, including age of patients with colorectal cancer (CRC) (p = 0.267), tumor location (p = 0.494), tumor differentiation grade (p = 0.263), neural tissue invasion, and 5-year survival (p = 0.054). Conclusion: CD133 is a useful predictive or prognostic biomarker for CRC in clinical assessment and may serve as a potential therapeutic target for CRC. © 2022, The Author(s).
Other Related Docs
20. Cd44 Polymorphisms and Its Variants, As an Inconsistent Marker in Cancer Investigations, Mutation Research - Reviews in Mutation Research (2021)
21. Trends in Colorectal Cancer Incidence in Iran, Journal of Mazandaran University of Medical Sciences (2015)
22. Ret Protein Expression in Colorectal Cancer; an Immunohistochemical Assessment, Asian Pacific Journal of Cancer Prevention (2021)
45. Gastrointestinal Cancers, Cancer Genetics and Psychotherapy (2017)